Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Development of blood tests for early lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 738
Rating:

Dr Geoffrey Oxnard - Dana-Farber Cancer Institute, Boston, USA

Dr Oxnard speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the prospects of a simple blood test for cell-free DNA (cfDNA) to detect lung cancers.

He discusses how 3 assays for targeted sequencing, whole-genome sequencing and whole-genome bisulfites sequencing can detect the circulating biomarkers of lung cancer, and considers how these could eventually be incorporated into screening and care.

For more on these results, watch his presentation of the results at the conference, and read our news coverage here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
 

Related videos

18.10.18

no rating
For HSCT in Ph-positive ALL

follow us

Breast cancer epidemiology video


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation